Hiran Orgochem Ltd
Hiran Orgochem is a leading integrated manufacturer of active pharmaceutical ingredients and formulations.
- Market Cap ₹ Cr.
- Current Price ₹ 0.48
- High / Low ₹ /
- Stock P/E
- Book Value ₹ -6.23
- Dividend Yield 0.00 %
- ROCE %
- ROE %
- Face Value ₹ 10.0
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Dividend Payout % |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Equity Capital |
| Reserves |
| Total Liabilities |
| CWIP |
| Investments |
| Total Assets |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Net Cash Flow |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Debtor Days |
| Inventory Days |
| Days Payable |
| Cash Conversion Cycle |
| Working Capital Days |
| ROCE % |
Documents
Announcements
-
Disclosure under Reg. 30 of SEBI (LODR) Regulations, 2015
31 Aug 2016 - Hiran Orgochem Ltd has informed BSE regarding Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015.
- Limited Review Report for June 30, 2016 12 Aug 2016
- Outcome of Board Meeting 11 Aug 2016
- Fixes Book Closure for AGM (Cut-off date for e-voting) 11 Aug 2016
- Standalone & Consolidated Financial Results, Limited Review Report for June 30, 2016 11 Aug 2016